160 related articles for article (PubMed ID: 26241744)
1. Computational Structure-Based De Novo Design of Hypothetical Inhibitors against the Anti- Inflammatory Target COX-2.
Dhanjal JK; Sreenidhi AK; Bafna K; Katiyar SP; Goyal S; Grover A; Sundar D
PLoS One; 2015; 10(8):e0134691. PubMed ID: 26241744
[TBL] [Abstract][Full Text] [Related]
2. Structural Probing, Screening and Structure-Based Drug Repositioning Insights into the Identification of Potential Cox-2 Inhibitors from Selective Coxibs.
Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
Interdiscip Sci; 2019 Jun; 11(2):153-169. PubMed ID: 29236213
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent cyclooxygenase-2 inhibitor, S4, through docking-based pharmacophore screening, in vivo and in vitro estimations.
Tseng TS; Chuang SM; Hsiao NW; Chen YW; Lee YC; Lin CC; Huang C; Tsai KC
Mol Biosyst; 2016 Jul; 12(8):2541-51. PubMed ID: 27265567
[TBL] [Abstract][Full Text] [Related]
4. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
5. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V
Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
[TBL] [Abstract][Full Text] [Related]
6. Cycloxygenase-2 (COX-2)--a potential target for screening of small molecules as radiation countermeasure agents: an in silico study.
Joshi J; Barik TK; Shrivastava N; Dimri M; Ghosh S; Mandal RS; Ramachandran S; Kumar IP
Curr Comput Aided Drug Des; 2013 Mar; 9(1):35-45. PubMed ID: 23905928
[TBL] [Abstract][Full Text] [Related]
7. The COXIB experience: a look in the rearview mirror.
Marnett LJ
Annu Rev Pharmacol Toxicol; 2009; 49():265-90. PubMed ID: 18851701
[TBL] [Abstract][Full Text] [Related]
8. Surface plasmon resonance studies and biochemical evaluation of a potent peptide inhibitor against cyclooxygenase-2 as an anti-inflammatory agent.
Somvanshi RK; Kumar A; Kant S; Gupta D; Singh SB; Das U; Srinivasan A; Singh TP; Dey S
Biochem Biophys Res Commun; 2007 Sep; 361(1):37-42. PubMed ID: 17640617
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, evaluation and molecular modelling studies of some novel 5,6-diphenyl-1,2,4-triazin-3(2H)-ones bearing five-member heterocyclic moieties as potential COX-2 inhibitors: A hybrid pharmacophore approach.
Banerjee AG; Das N; Shengule SA; Sharma PA; Srivastava RS; Shrivastava SK
Bioorg Chem; 2016 Dec; 69():102-120. PubMed ID: 27750057
[TBL] [Abstract][Full Text] [Related]
10. Computer-aided identification of natural lead compounds as cyclooxygenase-2 inhibitors using virtual screening and molecular dynamic simulation.
Ounissi M; Kameli A; Tigrine C; Rachedi FZ
Comput Biol Chem; 2018 Dec; 77():1-16. PubMed ID: 30195234
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
Coruzzi G; Venturi N; Spaggiari S
Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
[TBL] [Abstract][Full Text] [Related]
13. Interactions of selected indole derivatives with COX-2 and their in silico structure modifications towards the development of novel NSAIDs.
Dileep KV; Remya C; Tintu I; Sadasivan C
J Biomol Struct Dyn; 2014; 32(11):1855-63. PubMed ID: 24053423
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities.
Alanazi AM; El-Azab AS; Al-Suwaidan IA; ElTahir KE; Asiri YA; Abdel-Aziz NI; Abdel-Aziz AA
Eur J Med Chem; 2015 Mar; 92():115-23. PubMed ID: 25549551
[TBL] [Abstract][Full Text] [Related]
15. Aryl/heteroaryl Substituted Celecoxib Derivatives as COX-2 Inhibitors: Synthesis, Anti-inflammatory Activity and Molecular Docking Studies.
Madhava G; Ramana KV; Sudhana SM; Rao DS; Kumar KH; Lokanatha V; Rani AU; Raju CN
Med Chem; 2017; 13(5):484-497. PubMed ID: 28228088
[TBL] [Abstract][Full Text] [Related]
16. Visnagin and benzofuran scaffold-based molecules as selective cyclooxygenase-2 inhibitors with anti-inflammatory and analgesic properties: design, synthesis and molecular docking.
Khalil HS; Sedky NK; Amin KM; Abd Elhafez OM; Arafa RK
Future Med Chem; 2019 Apr; 11(7):659-676. PubMed ID: 30958028
[TBL] [Abstract][Full Text] [Related]
17. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
Hersh EV; Lally ET; Moore PA
Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
[TBL] [Abstract][Full Text] [Related]
18. Design & synthesis of novel oxazolone & triazinone derivatives and their biological evaluation as COX-2 inhibitors.
Mohamed LW; El-Badry OM; El-Ansary AK; Ismael A
Bioorg Chem; 2017 Jun; 72():308-314. PubMed ID: 28500957
[TBL] [Abstract][Full Text] [Related]
19. Photoelectron spectroscopy of non-steroidal anti-inflammatory drugs.
Novak I; Klasinc L; Chong DP; McGlynn SP
Spectrochim Acta A Mol Biomol Spectrosc; 2013 Aug; 112():110-5. PubMed ID: 23659958
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: gastrointestinal-sparing potential drugs.
Singh R; Kumar R; Singh DP
J Med Food; 2009 Feb; 12(1):208-18. PubMed ID: 19298218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
